S-Nitrosation Mediates Multiple Pathways That Lead to Tumor Progression in Estrogen Receptor-Negative Breast Cancer.

Chronic inflammation within the tumor microenvironment is a major driver of tumor progression and poor prognosis. Inducible nitric oxide synthase (NOS2) is present in numerous solid tumors. Estrogen receptor-negative (ER-) patients with high expression of tumor NOS2 have a poorer outcome than patients with low expression of NOS2. Furthermore, expression of NOS2 is associated with the basal-like breast cancer phenotype. Using an in vitro model, we have found that nitrosation of critical thiols and nitration of tyrosines lead to the activation of membrane receptors such as epithelial growth factor receptor, Src, Ras, and CD63. These nitric oxide-mediated events in itiate oncogenic signaling pathways such as PI3K/Akt, Ras/ERK, β-catenin, nuclear factor-κB, and AP-1. These data suggest that NOS2 can serve as a major "nonmutatational driver" of ER- breast cancer.

[1]  S. Ambs,et al.  Ets-1 is a transcriptional mediator of oncogenic nitric oxide signaling in estrogen receptor-negative breast cancer , 2012, Breast Cancer Research.

[2]  S. Ambs,et al.  Nitric Oxide Synthase and Breast Cancer: Role of TIMP-1 in NO-mediated Akt Activation , 2012, PloS one.

[3]  S. Ambs,et al.  S-Nitrosylation of EGFR and Src Activates an Oncogenic Signaling Network in Human Basal-Like Breast Cancer , 2012, Molecular Cancer Research.

[4]  A. Patruno,et al.  Activity of matrix metallo proteinases (MMPs) and the tissue inhibitor of MMP (TIMP)‐1 in electromagnetic field‐exposed THP‐1 cells , 2012, Journal of cellular physiology.

[5]  H. E. Marshall,et al.  S-nitrosylation in the regulation of gene transcription. , 2012, Biochimica et biophysica acta.

[6]  S. Ambs,et al.  Dithiolethiones inhibit NF-κB activity via covalent modification in human estrogen receptor-negative breast cancer. , 2012, Cancer research.

[7]  A. S. Krishnatry,et al.  Identification of nitroglycerin-induced cysteine modifications of pro-matrix metalloproteinase-9. , 2011, Rapid communications in mass spectrometry : RCM.

[8]  J. Stamler,et al.  Glioma Stem Cell Proliferation and Tumor Growth Are Promoted by Nitric Oxide Synthase-2 , 2011, Cell.

[9]  C. Colton,et al.  Nitric oxide and redox mechanisms in the immune response , 2011, Journal of leukocyte biology.

[10]  S. Ambs,et al.  Candidate pathways linking inducible nitric oxide synthase to a basal-like transcription pattern and tumor progression in human breast cancer , 2011, Cell cycle.

[11]  R. Stephens,et al.  Increased NOS2 predicts poor survival in estrogen receptor-negative breast cancer patients. , 2010, The Journal of clinical investigation.

[12]  T. Senga,et al.  S-Nitrosylation at Cysteine 498 of c-Src Tyrosine Kinase Regulates Nitric Oxide-mediated Cell Invasion* , 2009, The Journal of Biological Chemistry.

[13]  J. Stamler,et al.  Protein S-nitrosylation in health and disease: a current perspective. , 2009, Trends in molecular medicine.

[14]  R. Busuttil,et al.  Inducible nitric oxide synthase deficiency impairs matrix metalloproteinase-9 activity and disrupts leukocyte migration in hepatic ischemia/reperfusion injury. , 2009, The American journal of pathology.

[15]  Leah E. Mechanic,et al.  Nitric oxide is a key component in inflammation-accelerated tumorigenesis. , 2008, Cancer research.

[16]  S. Ambs,et al.  Molecular mechanisms for discrete nitric oxide levels in cancer. , 2008, Nitric oxide : biology and chemistry.

[17]  C. Harris,et al.  The chemical biology of nitric oxide: implications in cellular signaling. , 2008, Free radical biology & medicine.

[18]  Judith E. Cartwright,et al.  S-nitrosylation of proteins at the leading edge of migrating trophoblasts by inducible nitric oxide synthase promotes trophoblast invasion. , 2008, Experimental cell research.

[19]  F. Liew,et al.  Nitric oxide induces CD4+CD25+ Foxp3− regulatory T cells from CD4+CD25− T cells via p53, IL-2, and OX40 , 2007, Proceedings of the National Academy of Sciences.

[20]  S. Ambs,et al.  Inflammation and IGF‐I activate the Akt pathway in breast cancer , 2007, International journal of cancer.

[21]  C. Harris,et al.  Hypoxic inducible factor 1α, extracellular signal-regulated kinase, and p53 are regulated by distinct threshold concentrations of nitric oxide , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[22]  D. Wink,et al.  Inhibition of poly(ADP-RIBOSE) polymerase (PARP) by nitric oxide and reactive nitrogen oxide species. , 2003, Free radical biology & medicine.

[23]  D. Celermajer,et al.  Nitroglycerin upregulates matrix metalloproteinase expression by human macrophages. , 2002, Journal of the American College of Cardiology.

[24]  W. Parks,et al.  Hypochlorous Acid Oxygenates the Cysteine Switch Domain of Pro-matrilysin (MMP-7) , 2001, The Journal of Biological Chemistry.

[25]  A. Buzaid,et al.  Inducible nitric oxide synthase and nitrotyrosine in human metastatic melanoma tumors correlate with poor survival. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[26]  X. Le,et al.  Influence of nitric oxide synthase II gene disruption on tumor growth and metastasis. , 2000, Cancer research.

[27]  C. Carlberg,et al.  Inactivation of zinc finger transcription factors provides a mechanism for a gene regulatory role of nitric oxide , 2000, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[28]  Y. Vodovotz,et al.  Regulation of transforming growth factor beta1 by nitric oxide. , 1999, Cancer research.

[29]  L. Thomsen,et al.  Role of nitric oxide in tumour progression: Lessons from human tumours , 1998, Cancer and Metastasis Reviews.

[30]  C. Harris,et al.  Frequent nitric oxide synthase-2 expression in human colon adenomas: implication for tumor angiogenesis and colon cancer progression. , 1998, Cancer research.

[31]  I. Stamenkovic,et al.  Induction of Apoptosis of Metastatic Mammary Carcinoma Cells In Vivo by Disruption of Tumor Cell Surface CD44 Function , 1997, The Journal of experimental medicine.

[32]  C. Estrada,et al.  Nitric oxide reversibly inhibits the epidermal growth factor receptor tyrosine kinase. , 1997, The Biochemical journal.

[33]  B. Chait,et al.  A Molecular Redox Switch on p21ras , 1997, The Journal of Biological Chemistry.

[34]  P. Lagadec,et al.  Nitric oxide involvement in tumor-induced immunosuppression. , 1994, Journal of immunology.

[35]  J. Weiss,et al.  NOS2 enhances KRAS‐induced lung carcinogenesis, inflammation and microRNA‐21 expression , 2013, International journal of cancer.

[36]  O. Olopade,et al.  Stem Cells , Tissue Engineering and Hematopoietic Elements Wnt /-Catenin Pathway Activation Is Enriched in Basal-Like Breast Cancers and Predicts Poor Outcome , 2010 .

[37]  C. Harris,et al.  Nitric Oxide and Cancer: An Overview , 2010 .

[38]  B. Brüne,et al.  The role of nitric oxide (NO) in stability regulation of hypoxia inducible factor-1alpha (HIF-1alpha). , 2003, Current medicinal chemistry.